About Mammoth View
Mammoth View is a venture capital firm founded in 2002. It is primarily based out of Louisville, United States. It primarily invests in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to Enterprise Applications and HealthTech. Overall, Mammoth View portfolio has seen 2 IPOs and 17 acquisitions including key companies like Xometry, Apellis Pharmaceuticals and Mersive.Key Metrics
Portfolio Count
Portfolio Sectors
Portfolio Locations
Portfolio IPOs
Portfolio Acquisitions
Mammoth View's List of Top Investments
Mammoth View has a portfolio of 73 companies. Their most notable investments include Xometry and Apellis Pharmaceuticals.Their portfolio spans across United States and Canada. They have invested in Life Sciences, Enterprise Applications, HealthTech and 19 other sectors. Here is the list of top investments by Mammoth View:1. Xometry
Provider of on-demand custom manufacturing platform for prototypes and production parts. The company connects buyers with a network of vetted suppliers offering instant quoting for CNC machining, 3D printing, sheet metal fabrication, injection molding, urethane casting, and metal stamping processes. Its platform supports rapid prototyping through high-volume production with no minimum orders, providing materials like metals, plastics, and composites along with finishing options and assembly services. Digital tools enable file upload, design analysis, project management, and supply chain traceability for startups to enterprises.
Key facts about Xometry
- Founded Year: 2013
- Location: Washington, DC (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $200M
- Employee Count: 1,164 as on Jul 31, 2026
- Investors: HTIF, ADS Ventures and 20 Others
- Latest Funding Round: Post IPO, Feb 01, 2022, $*****
- Highlight: Public
Developer of therapeutics for the treatment of rare diseases. The company is developing transformative therapies for people living with a broad range of debilitating diseases by controlling complement, part of the body’s immune system. The company develops programs across ophthalmology, nephrology, hematology, and neurology.
Key facts about Apellis Pharmaceuticals
- Founded Year: 2008
- Location: Crestwood (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $213M
- Employee Count: 568 as on Jul 31, 2026
- Investors: Avoro Capital, VenBio and 21 Others
- Latest Funding Round: Post IPO, May 07, 2020, $*****
- Highlight: Acquired

3. Mersive
Mersive Technologies builds collaboration technology designed for the way people actually work. From wireless content sharing to cloud-managed meeting rooms, Mersive's platforms help IT teams deploy and manage spaces at scale while giving employees and guests a seamless, friction-free experience. With hardware-rooted security and intuitive cloud management platforms, Mersive turns every room into a smarter, more capable space and keeps it that way.
Key facts about Mersive
- Founded Year: 2006
- Location: Lakewood (United States)
- Stage: Acquired
- Total Funding till date: $13.2M
- Employee Count: 58 as on Jul 31, 2026
- Investors: Razor's Edge Ventures, Bluegrass Angels and 7 Others
- Latest Funding Round: Series C, Oct 15, 2014, $*****
- Highlight: Acquired
Developer of therapeutics for the treatment of multiple diseases. The company's drugs include APOKYN (apomorphine hydrochloride injection for Parkinson's disease), CORGARD (nadolol tablets for hypertension, angina pectoris), MYOBLOC (rimabotulinumtoxinB Injection for cervical dystonia), REVONTO (dantrolene sodium injection for anesthetic-induced malignant hyperthermia syndrome) and XADAGO (safinamide tablets for Parkinson's Disease).
Key facts about US World Meds
- Founded Year: 2001
- Location: Louisville (United States)
- Stage: Series B
- Total Funding till date: $149M
- Employee Count: 216 as on Dec 31, 2019
- Investors: Athyrium Capital Management, CRG and 6 Others
- Latest Funding Round: Grant (prize money), Jul 17, 2025, $*****
Provider of solutions for demand response and energy intelligence. It integrates with (IoT)-based devices from third-party device manufacturers and connects to those devices through the device manufacturer's server, using secure server-to-server communication systems. It applies machine learning and real-time control to devices to reduce demand. It offers utilities the power to control demand and also provides data about consumption to the users. Additionally, provides mobile and web applications that can bring together smart device data and billing information to provide a one-stop customer engagement platform.
Key facts about Virtual Peaker
- Founded Year: 2015
- Location: Louisville (United States)
- Stage: Series A
- Total Funding till date: $19.8M
- Employee Count: 70 as on Jul 31, 2026
- Investors: Moore Strategic Ventures, FreshTracks Capital and 5 Others
- Latest Funding Round: Conventional Debt, May 15, 2026, $*****
- Highlight: Editors' Pick
IPOs and Publicly Listed companies in Mammoth View's Portfolio
2 of Mammoth View's portfolio companies have become public. ZYUS Life Sciences got listed on the Toronto Stock Exchange (TSX), in Jun 2023 and Xometry got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $1.77B.Here are Mammoth View's portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jun 23, 2023 | - | - | 2025 | |
Jun 30, 2021 | - | - | 7200 |
Acquired companies in Mammoth View's Portfolio
17 companies from Mammoth View's portfolio have been acquired. The most recent acquisition was Apellis Pharmaceuticals in Mar 2026 by Biogen for $*****.Here are Mammoth View's portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Mar 31, 2026 | - | - | 6193 | |
Dec 20, 2025 | - | - | 7485 | |
Feb 18, 2025 | - | - | 8561 | |
Jan 18, 2024 | - | - | 5409 | |
Nov 02, 2023 | - | - | 3216 |

